| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/19/2003 | CN1397557A NOvel octahydro-2H-pyridino-[1,2-a] pyrazine compound, its prepn. process and medicinal compound contg. them |
| 02/19/2003 | CN1397556A Alkali-metal or alkali-earth metal salt of polyprotic acid delotadine and its medical composition |
| 02/19/2003 | CN1397293A 南瓜散 Pumpkin Powder |
| 02/19/2003 | CN1397197A Health-care food for nutritive and purposes |
| 02/19/2003 | CN1397182A Hypoglycemic health-care tea and its preparing process |
| 02/19/2003 | CN1101816C Substituted purine derivatives, processes for their prepn. their use, and compsns. comprising them |
| 02/19/2003 | CN1101699C Defatting traditional Chinese medicine |
| 02/19/2003 | CN1101695C Application of medicine from plant extracts for treatment of increase bone resorption, and compsns, thereof |
| 02/19/2003 | CN1101684C Bee worm calcium preparation |
| 02/18/2003 | WO2002016329A1 Novel phenylalanine derivatives |
| 02/18/2003 | US6521666 Inhibitors of α4 mediated cell adhesion |
| 02/18/2003 | US6521665 Method of treating insulin resistance |
| 02/18/2003 | US6521654 Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them |
| 02/18/2003 | US6521652 Thiazoline acid derivatives |
| 02/18/2003 | US6521646 Integrin inhibitors |
| 02/18/2003 | US6521643 Pyridine compounds and their pharmaceutical use |
| 02/18/2003 | US6521640 Method for interviewing neuronal death using sulfasalazine |
| 02/18/2003 | US6521615 Administering calcium antagonist and reducing calcium pyrophosphate crystal deposition in an animal with pyrophosphate gout or osteoarthritis; diltiazem, nifedipine |
| 02/18/2003 | US6521608 Pulsed administration that avoids development of severe symptomatic or life threatening hypercalcemia |
| 02/18/2003 | US6521248 Cavitation; reduced pressure; oxygenated water |
| 02/18/2003 | US6521226 Administering Paraoxonase-1 (PON-1), an expressed protein that has hydrolase activity for organophosphates, and antioxidation activity for low-density lipoprotein (LDL) |
| 02/18/2003 | CA2420042A1 Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient |
| 02/18/2003 | CA2073042C Phenylethanolamines, drugs containing these compounds, and a method of preparing them |
| 02/15/2003 | CA2392309A1 Neuropeptide receptor and uses thereof |
| 02/15/2003 | CA2392305A1 Adrenic acid receptor and uses thereof |
| 02/14/2003 | WO2002018326A1 Novel propenohydroxamic acid derivatives |
| 02/14/2003 | CA2423733A1 Novel propenohydroxamic acid derivatives |
| 02/13/2003 | WO2003012441A1 Method for detecting modulators of notch signalling |
| 02/13/2003 | WO2003012139A2 Methods for assessing the risk of obesity based on allelic variations in the 5'-flanking region of the insulin gene |
| 02/13/2003 | WO2003012122A2 Crystallized structure of type iv collagen nc1 domain hexamer |
| 02/13/2003 | WO2003012112A1 Methylation resistant vectors |
| 02/13/2003 | WO2003012111A2 Conjugates for the modulation of immune responses |
| 02/13/2003 | WO2003012105A2 Vegf isoform |
| 02/13/2003 | WO2003012104A1 Novel g protein-coupled receptor protein and dna thereof |
| 02/13/2003 | WO2003011906A2 Use of peptide fragments of the calcium channel α-1 subunit, optionally comprising mutations, for screening molecules of therapeutic interest |
| 02/13/2003 | WO2003011892A2 Glp-1 exendin-4 peptide analogs and uses thereof |
| 02/13/2003 | WO2003011887A2 Antisense modulation of apolipoprotein b expression |
| 02/13/2003 | WO2003011880A1 Glucopyrano syloxybenzyl benzene derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| 02/13/2003 | WO2003011868A1 Thienopyrimidinediones and their use in the modulation of autoimmune disease |
| 02/13/2003 | WO2003011856A1 Aminoalkylimidazole derivatives preparation and therapeutic use thereof |
| 02/13/2003 | WO2003011855A2 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/13/2003 | WO2003011854A1 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/13/2003 | WO2003011852A1 Novel modifications of the trometamol salt of r-thioctic acid and method for producing the same |
| 02/13/2003 | WO2003011843A1 Novel 2,4-diaminothiazole derivatives |
| 02/13/2003 | WO2003011842A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 02/13/2003 | WO2003011839A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| 02/13/2003 | WO2003011835A1 Benzimidazolylalkyl-aryl(alkan) oic acid derivatives and their use as antihyperglycaemics |
| 02/13/2003 | WO2003011834A1 Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
| 02/13/2003 | WO2003011830A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 02/13/2003 | WO2003011826A1 Crystalline forms vi and vii of atorvastatin calcium |
| 02/13/2003 | WO2003011819A1 Butyric acid derivatives |
| 02/13/2003 | WO2003011814A1 Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
| 02/13/2003 | WO2003011807A1 Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc. |
| 02/13/2003 | WO2003011396A1 Tetrahydroindolone and purine derivatives linked to arylpiperazines |
| 02/13/2003 | WO2003011339A1 Composition for epigallocatechin gallate |
| 02/13/2003 | WO2003011325A1 Agonists and antagonists of moceptin for the treatment of metabolic disorders |
| 02/13/2003 | WO2003011324A1 Agonists and antagonists of moxifin for the treatment of metabolic disorders |
| 02/13/2003 | WO2003011323A1 Agonists and antagonists of contabix for use in the treatment of metabolic disorders |
| 02/13/2003 | WO2003011322A1 Agonists and antagonists of genoxin for use in the treatment of metabolic disorders |
| 02/13/2003 | WO2003011321A1 Agonists and antagonists of cobesin for the treatment of metabolic disorders |
| 02/13/2003 | WO2003011320A1 Agonists and antagonists of obesingen for the treatment of metabolic disorders |
| 02/13/2003 | WO2003011319A1 Xobesin agonists and antagonists for the treatment of metabolic disorders |
| 02/13/2003 | WO2003011318A1 Agonists and antagonists of famoset for use in the treatment of metabolic disorders |
| 02/13/2003 | WO2003011317A1 Modulators of notch signalling for use in immunotherapy |
| 02/13/2003 | WO2003011311A1 Bauhinia extracts |
| 02/13/2003 | WO2003011309A2 Pharmaceutical composition for treating hypercholesterolaemia |
| 02/13/2003 | WO2003011308A1 Drugs for ameliorating postcibal hyperglycemia |
| 02/13/2003 | WO2003011304A1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity |
| 02/13/2003 | WO2003011302A1 Androgen receptor modulators and methods of use thereof |
| 02/13/2003 | WO2003011288A1 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists |
| 02/13/2003 | WO2003011287A1 Pyrazolon derivatives as inhibitors of gsk-3 |
| 02/13/2003 | WO2003011285A1 BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES |
| 02/13/2003 | WO2003011284A1 5-arylsulfonyl indoles having 5-ht6 receptor affinity |
| 02/13/2003 | WO2003011283A1 Pharmaceutical compositions of amlodipine and atorvastatin |
| 02/13/2003 | WO2003011279A1 (-)-olivil as antioxidant |
| 02/13/2003 | WO2003011276A1 Nf?b inhibitor |
| 02/13/2003 | WO2003011275A1 Swine growth promoters and method of promoting swine growth |
| 02/13/2003 | WO2003011273A1 Metformin in the treatment of hyperglycemic conditions |
| 02/13/2003 | WO2003011268A1 (+)-cycloolivil as antioxidant obtained from stereospermum personatum |
| 02/13/2003 | WO2003011267A1 Antiobesity drugs and materials thereof |
| 02/13/2003 | WO2003011262A2 Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with cgmp regulated processes |
| 02/13/2003 | WO2003011252A1 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety |
| 02/13/2003 | WO2003011227A2 Taste masking composition |
| 02/13/2003 | WO2003011225A2 Calcium glutarate supplement and phosphorus binder |
| 02/13/2003 | WO2003011221A2 PREPARATION AND USE OF α-KETO PHOSPHONATES |
| 02/13/2003 | WO2003011213A2 Method for treating diabetes and obesity |
| 02/13/2003 | WO2003011207A2 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine |
| 02/13/2003 | WO2003011055A1 Nutritional composition preventing bacterial overgrowth |
| 02/13/2003 | WO2003011042A1 Soluble roasted chicory with high inulin content |
| 02/13/2003 | WO2003004016A8 Use of substituted gamma-lactone compounds as medicaments |
| 02/13/2003 | WO2002088146A3 ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF 2,3-DIHYDRO-7H-[1,4]DIOXINO[2,3-e]INDOLE |
| 02/13/2003 | WO2002076995A3 2-amino-propanol derivatives |
| 02/13/2003 | WO2002072591A3 Resveratrol-phospholipids complexes |
| 02/13/2003 | WO2002062810A3 Linkable sialyl lewis x analogs |
| 02/13/2003 | WO2002059082A8 Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |
| 02/13/2003 | WO2002055556A3 Regulation of human voltage gated potassium channel protein kv2.2 |
| 02/13/2003 | WO2002047719A3 Survical promoting ncam binding and ncam ligand biding compounds |
| 02/13/2003 | WO2002038129A3 Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
| 02/13/2003 | WO2002032958A3 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors |
| 02/13/2003 | WO2002031115A3 Nucleic acid molecules and polypeptides for immune modulation |